News
Ambros' $125m for pain disorder drug, and other financings
Our latest crop of biofinancings has nine-figure rounds for Ambros, Atavistik, Orum, and Addition, with Link Cell and Aeovian also raising new funds.
News
J&J's subcutaneous Rybrevant cleared by FDA
J&J has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of the lung cancer therapy central to its blockbuster hopes for the drug.
News
Datroway filed for TNBC in EU after data delay
Daiichi Sankyo and AstraZeneca have filed their first marketing application for TROP2-targeting Datroway in triple-negative breast cancer.
News
MSD claims two national priority vouchers; report
The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD drug candidates.
News
As year-end nears, pharma groups plump up their pipelines
Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
